Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.
Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, Braumüller H, Schmitt J, Eyrich M, Schleicher S, Seitz C, Erbacher A, Pichler BJ, Müller H, Tighe R, Lim A, Gillies SD, Strittmatter W, Röcken M, Handgretinger R.
Schilbach K, et al. Among authors: gillies sd.
Oncoimmunology. 2015 Mar 19;4(7):e1014760. doi: 10.1080/2162402X.2015.1014760. eCollection 2015 Jul.
Oncoimmunology. 2015.
PMID: 26140238
Free PMC article.